【作者】 张涛；

【导师】 陈亮；

【作者基本信息】 河北医科大学 ， 外科学（专业学位）， 2023， 硕士

【摘要】 目的:比较白蛋白结合型紫杉醇与多西他赛对晚期三阴性乳腺癌解救治疗的短期疗效与不良反应。方法:选取2017年10月-2022年10月就诊于沧州市中心医院确诊为晚期三阴性乳腺癌的女性患者共51例,其中白蛋白结合型紫杉醇组(N ab组)25例,给予白蛋白结合型紫杉醇(Nab-紫杉醇)静脉滴注260mg/m~2/次,3周为一周期;卡培他滨口服1000mg/m~2/次,2次/天,持续1-14天,3周为一周期。多西他赛组26例,给予多西他赛静脉滴注75mg/m~2/次,3周为一周期;卡培他滨口服1000mg/m~2/次,2次/天,持续1-14天,3周为一周期。结果:Nab组中平均年龄55.68±9.03岁。中位化疗4.0(4.0,5.5)周期,多西他赛组平均年龄53.50±9.13岁,中位化疗6.0(4.0,8.0)周期,化疗周期多西他赛组高于Nab组,两组相比有统计学意义(Z=-2.083,P=0.037)。两组均无达到完全缓解的病例,ORR和DCR无统计学意义(P>0.05),同样两组TTP无统计学意义(P>0.05)。Nab组与多西他赛组不良反应比较中,Nab组周围神经病变、胃肠道反应、疲劳等不良反应发生高于多西他赛组,差异有统计学意义(P<0.05)。而在白细胞减少、血红蛋白减少、血小板减少、红斑及水肿、关节及肌肉痛等不良反应中,两组无明显差异,无统计学意义(P>0.05)。结论:综上所述,在对晚期三阴性乳腺癌的解救治疗中,Nab-紫杉醇与多西他赛的短期疗效可能无明显差异,患者对多西他赛耐受性可能优于Nab-紫杉醇,胃肠道反应、周围神经病变和疲劳在Nab-紫杉醇治疗过程中更常见,两种药物造成的不良反应可控。更多还原

【Abstract】 Objective:To compare the short-term efficacy and side effects of nab-paclitaxel and docetaxel in salvage therapy of advanced triple-negative breast cancer.Methods:A total of 51 female patients diagnosed with advanced triple-negative breast cancer in Cangzhou Central Hospital from October 2017to October 2022 were selected.Among them,25 cases were given intravenous drip of nab-paclitaxel(260mg/m~2 iv.drip)and capecitabine(1000mg/m~2,po.bid d1-d14)for 3 weeks as a cycle;the other 26 cases were given docetaxel(75mg/m~2 iv.drip)and capecitabine(1000mg/m~2,po.bid d1-d14),3 weeks as a cycle.Results:The average age of nab-paclitaxel group was 55.68±9.03 years,the median cycle of chemotherapy was 4.0(4.0,5.5)cycles,while the average age of docetaxel group was 53.5±9.13 years,and the median cycle of chemotherapy was 6(4.0,8.0)cycles.The cycle of chemotherapy in docetaxel group was significantly higher than that in nab-paclitaxel group(P<0.05).There were no cases of complete remission in both groups.ORR and DCR were no statistical significance between the two groups.In the comparison of adverse reactions between the nab-paclitaxel group and the docetaxel group,the adverse reactions such as peripheral neuropathy,gastrointestinal reaction and fatigue in the nab-paclitaxel group were significantly higher than those in the docetaxel group(P<0.05).There was no significant difference in adverse reactions such as leukopenia,hemoglobin,thrombocytopenia,erythema and edema,joint and muscle pain between the two groups(P>0.05).Conclusions:In the salvage treatment of advanced triple-negative breast cancer,There may be no significant difference in short-term efficacy between Nab-paclitaxel and docetaxel.The patient’s tolerance to docetaxel may be better than that of Nab-paclitaxel,and gastrointestinal reactions,peripheral neuropathy and fatigue during the treatment of Nab-paclitaxel More commonly,adverse effects caused by both drugs were manageable.更多还原